Answers are grounded in this paper and cite their sources.
Background: Treatment of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) has evolved from first-generation tyrosine kinase inhibitors (TKIs) to third-generation osimertinib and, more recently, to intensified first-line regimens. Osimertinib monotherapy remains effective and comparatively tolerable, while osimertinib plus platinum-pemetrexed and amivantamab plus lazertinib improve progression-free and overall survival at the cost of greater toxicity. This article evaluates current first- and subsequent-line treatment strategies for advanced NSCLC harboring common sensitizing EGFR mutations (exon 19 deletions or exon 21 L858R substitutions), with particular attention to efficacy, toxicity, resistance mechanisms, and patient selection. Methods: A structured assessment of phase III randomized trials, published network meta-analyses and indirect comparisons, and resistance-focused literature was conducted to compare efficacy, toxicity, resistance mechanisms, costs, and patient-selection considerations across current treatments. No original statistical analysis was performed; comparative estimates were derived from published studies. Results: First-line intensification with osimertinib plus chemotherapy or amivantamab plus lazertinib improves progression-free survival (PFS) and overall survival (OS) over osimertinib alone in EGFR-mutant NSCLC, particularly in high-risk patients, but it also increases toxicity, and resistance remains heterogeneous and may require repeat molecular profiling to guide further therapy. Published indirect comparisons have not shown a significant difference between the two intensified regimens. Conclusions: No single regimen suits all patients. Fit patients with high-risk features may derive the greatest absolute benefit from first-line intensification. Apparent differences between osimertinib plus platinum-pemetrexed and amivantamab plus lazertinib in subgroups (such as L858R or TP53 co-mutation) are based mainly on exploratory cross-trial data and do not establish superiority of either regimen. Amivantamab plus lazertinib offers a chemotherapy-free alternative with a distinct toxicity profile. Osimertinib monotherapy remains appropriate for patients with lower-risk disease, frailty, poorer performance status, or significant comorbidities, or for those who prefer a lower treatment burden; age alone should not determine treatment choice. Post-progression therapy should be guided by repeat biopsy, plasma genotyping, and identified resistance mechanisms.
No takes yet. Share an insight, caveat, or question.
Shrem et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: